CRDF vs. CGEN, ADVM, CLLS, VXRT, CRDL, XFOR, VCXB, KOD, LIFE, and VIGL
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Compugen (CGEN), Adverum Biotechnologies (ADVM), Cellectis (CLLS), Vaxart (VXRT), Cardiol Therapeutics (CRDL), X4 Pharmaceuticals (XFOR), 10X Capital Venture Acquisition Corp. III (VCXB), Kodiak Sciences (KOD), aTyr Pharma (LIFE), and Vigil Neuroscience (VIGL). These companies are all part of the "biological products, except diagnostic" industry.
Compugen (NASDAQ:CGEN) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk.
12.2% of Compugen shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 7.6% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Compugen had 6 more articles in the media than Cardiff Oncology. MarketBeat recorded 8 mentions for Compugen and 2 mentions for Cardiff Oncology. Compugen's average media sentiment score of 1.88 beat Cardiff Oncology's score of 0.44 indicating that Cardiff Oncology is being referred to more favorably in the news media.
Compugen received 267 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 64.48% of users gave Compugen an outperform vote while only 62.30% of users gave Cardiff Oncology an outperform vote.
Compugen has a net margin of 0.00% compared to Compugen's net margin of -6,594.92%. Cardiff Oncology's return on equity of -27.75% beat Compugen's return on equity.
Compugen has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.
Compugen has higher revenue and earnings than Cardiff Oncology. Compugen is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Compugen currently has a consensus target price of $4.00, suggesting a potential upside of 58.73%. Cardiff Oncology has a consensus target price of $10.50, suggesting a potential upside of 223.08%. Given Compugen's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Compugen.
Summary
Compugen beats Cardiff Oncology on 11 of the 16 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
